Following The Patents: Covid-19 & Medical Tyranny

 

Over the past two decades, a company named M·CAM has been monitoring possible violations of the 1925 Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare (the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of Bacteriological and Toxin Weapons and Their Destruction (the BTWC). In their 2003-2004 Global Technology Assessment: Vector Weaponization, M·CAM highlighted China’s growing involvement in Polymerase Chain Reaction (PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Since that time, on a weekly basis, they have monitored the development of research and commercial efforts in this field, including, but not limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC), the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC), Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, and many other research institutions, and their commercial affiliations.

 

The National Institute of Health’s grant AI23946-08, issued to Dr. Ralph Baric at the University of North Carolina at Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit. (Source: U.S. Provisional Application No. 60/206,537, filed May 21, 2000) In one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full-length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.

 

“Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones.” (Source: https://www.pnas.org/content/100/22/12995)

 

On April 19, 2002, the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first public record of the claims, they sought to patent a means of producing, “an infectious, replication defective, coronavirus.” This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 before SARS was ever detected in humans!

 

Against this backdrop, they noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003 SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Work associated with this virus by their select collaborators included considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment (both vaccine and therapeutic intervention), and weaponization inquiries.

 

In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852 patent (Claim 1), no research in the United States could be conducted without permission or infringement.

 

It was noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research grants from several federal agencies but also sat on the World Health Organization’s International Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for determining “novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the form of new research funding authorizations and associated patenting and commercial collaboration. Together with CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of interests constituted what we would suggest are “interlocking directorates” under U.S. anti-trust laws.

 

These entities also were affiliated with the WHO’s Global Preparedness Monitoring Board (GPMB) whose members were instrumental in the Open Philanthropy-funded global coronavirus pandemic “desk-top” exercise EVENT 201 in October 2019. This event, funded by the principal investor in Sherlock Biosciences and linking interlocking funding partner, the Bill and Melinda Gates Foundation into the GPMB mandate for a respiratory disease global preparedness exercise to be completed by September 2020 alerted us to anticipate an “epidemic” scenario. We expected to see such a scenario emerge from Wuhan or Guangdong China, northern Italy, Seattle, New York or a combination thereof, as Dr. Zhengli Shi and Dr. Baric’s work on zoonotic transmission of coronavirus identified overlapping mutations in coronavirus in bat populations located in these areas.

35 U.S.C. § 101

 

Section 101 of the Patent Act:   "Whoever invents or discovers any new and useful ... composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title." 35 U.S.C. § 101.

 

We have "long held that this provision contains an important implicit exception[:] Laws of nature, natural phenomena, and abstract ideas are not patentable." Mayo, 566 U.S., at    , 132 S.Ct., at 1293 (internal quotation marks and brackets omitted). Rather, "`they are the basic tools of scientific and technological work'" that lie beyond the domain of patent protection. Id., at    , 132 S.Ct., at 1293. As the Court has explained, without this exception, there would be considerable danger that the grant of patents would "tie up" the use of such tools and thereby "inhibit future innovation premised upon them." Id., at     _, 132 S.Ct., at 1301. This would be at odds with the very point of patents, which exist to promote creation. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980) (Products of nature are not created, and "`manifestations... of nature [are] free to all men and reserved exclusively to none'").(Source: Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013))

 

In their majority opinion in 2013, the U.S. Supreme Court made it abundantly clear that the Court had “long held” that nature was not patentable. Merely isolating DNA does not constitute patentable subject matter. In their patent, the CDC made false and misleading claims to the United States Patent & Trademark Office by stating that, “A newly isolated human coronavirus has been identified as the causative agent of SARS, and is termed SARS-CoV.” (Source: U.S. Patent 7,220,852) No “causal” data was provided for this statement.

 

When they filed their patent application on April 25, 2003, their first claim (and the only one that survived to ultimate issuance over the objection of the patent examiner in 2006 and 2007) was the genome for SARS CoV.

 

While this patent is clearly illegal under 35 U.S.C. §101, not only did the CDC insist on its granting over non-final and final rejections, but they also continued to pay maintenance fees on the patent after the 2013 Supreme Court decision confirmed that it was illegal.

 

In addition, the CDC patented the detection of SARS CoV using a number of methods including reverse transcription polymerase chain reaction (RT-PCR). With this patent, they precluded anyone outside of their licensed or conspiring interest from legally engaging in independent verification of their claim that they had isolated a virus, that it was a causative agent for SARS, or that any therapy could be effective against the reported pathogen.

 

It is important to note that the CDC’s patent applications were also rejected in non-final and final rejections for ineligibility under 35 U.S.C. § 102 for being publicly disclosed prior to their own filing. In the first non-final rejection, the USPTO stated that the CDC’s genome was published in four Genbank accession entries on April 14, 18, and 21, 2003 with identity ranging from 96.8% to 99.9% identical sequences. (Source: USPTO Non-Final Rejection File #10822904, September 7, 2006, page 4.) Dr. Fauci knew, and failed to disclose evidence that the CDC patent was illegal, based on work he had funded in the years leading up to the SARS outbreak.

 

After seeking an illegal patent, petitioning to override the decision of an examiner to reject it, and ultimately prevailing with the patent’s grant, the CDC lied to the public by stating they were controlling the patent so that it would be “publicly available”. (Source: https://apnews.com/article/145b4e8d156cddc93e996ae52dc24ec0) Tragically, this public statement is falsified by the simple fact that their own publication in Genbank had, in fact, made it public domain and thereby unpatentable. This fact, confirmed by patent examiners, was overridden by CDC in a paid solicitation to override the law.

 

While not covered under 35 U.S.C. §101, Dr. Fauci’s abuse of the patent law is detailed below. Of note, however, is his willful and deceptive use of the term “vaccine” in patents and public pronouncements to pervert the meaning of the term for the manipulation of the public.

 

In the 1905 Jacobson v. Mass case, the court was clear that a PUBLIC BENEFIT was required for a vaccine to be mandated. Neither Pfizer nor Moderna have proved a disruption of transmission. In Jacobson v. Massachusetts, 197 U.S. 11 (1905), the court held that the context for their opinion rested on the following principle:

 

“This court has more than once recognized it as a fundamental principle that 'persons and property are subjected to all kinds of restraints and burdens in order to secure the general comfort, health, and prosperity of the state…”

 

The Moderna and Pfizer “alleged vaccine” trials have explicitly acknowledged that their gene therapy technology has no impact on viral infection or transmission whatsoever and merely conveys to the recipient the capacity to produce an S1 spike protein endogenously by the introduction of a synthetic mRNA sequence. Therefore, the basis for the Massachusetts statute and the Supreme Court’s determination is moot in this case.

Further, the USPTO, in its REJECTION of Anthony Fauci's HIV vaccine made the following statement supporting their rejection of his bogus "invention"

 

 

18 U.S.C. §2339 C et seq. – Funding and Conspiring to Commit Acts of Terror

Indirectly, unlawfully, and willfully provides or collects funds with the intention that such funds be used, or with the knowledge that such funds are to be used, in full or in part, in order to carry out—

1. an act which constitutes an offense within the scope of a treaty specified in subsection (e)(7), as implemented by the United States, or
2. any other act intended to cause death or serious bodily injury to a civilian, or to any other person not taking an active part in the hostilities in a situation of armed conflict, when the purpose of such act, by its nature or context, is to intimidate a population, or to compel a government or an international organization to do or to abstain from doing any act….

 

By no later than April 11, 2005, Dr. Anthony Fauci was publicly acknowledging the association of SARS with bioterror potential. Leveraging the fear of the anthrax bioterrorism of 2001, he publicly celebrated the economic boon that domestic terror had directed towards his budget. He specifically stated that NIAID was actively funding research on a “SARS Chip” DNA microarray to rapidly detect SARS (something that was not made available during the current “pandemic”) and two candidate vaccines focused on the SARS CoV spike protein. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/ ) Led by three Chinese researchers under his employment – Zhi-yong Yang, Wing-pui Kong, and Yue Huang – Fauci had at least one DNA vaccine in animal trials by 2004. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/ ) This team, part of the Vaccine Research Center at NIAID, was primarily focused on HIV vaccine development but was tasked to identify SARS vaccine candidates as well. Working in collaboration with Sanofi, Scripps Institute, Harvard, MIT and NIH, Dr. Fauci’s decision to unilaterally promote vaccines as a primary intervention for several designated “infectious diseases” precluded proven therapies from being applied to the sick and dying.(Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/)

 

The CDC and NIAID led by Anthony Fauci entered into trade among States (including, but not limited to working with EcoHealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent rights. This research was known to involve surface proteins in coronavirus that had the capacity to directly infect human respiratory systems. In flagrant violation of the NIH moratorium on gain of function research, NIAID and Ralph Baric persisted in working with chimeric coronavirus components specifically to amplify the pathogenicity of the biologic material.

 

By October 2013, the Wuhan Institute of Virology 1 coronavirus S1 spike protein was described in NIAID’s funded work in China. This work involved NIAID, USAID, and Peter Daszak, the head of EcoHealth Alliance. This work, funded under R01AI079231, was pivotal in isolating and manipulating viral fragments selected from sites across China which contained high risk for severe human response. (Source: Ge, XY., Li, JL., Yang, XL. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535–538 (2013).)

 

By March 2015, both the virulence of the S1 spike protein and the ACE II receptor was known to present a considerable risk to human health. NIAID, EcoHealth Alliance and numerous researchers lamented the fact that the public was not sufficiently concerned about coronavirus to adequately fund their desired research.(Source: Forum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington (DC): National Academies Press (US); 2016 Feb 12. 6, Developing MCMs for Coronaviruses. Available from: https://www.ncbi.nlm.nih.gov/books/NBK349040/)

 

Dr. Peter Daszak of EcoHealth Alliance offered the following assessment:

  

“Daszak reiterated that, until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the need for MCMs such as a pan-influenza or pan-coronavirus vaccine. A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of process, Daszak stated.”

 

Economics will follow the hype.

 

The CDC and NIAID entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016. These projects took place during a time when the work being performed was prohibited by the United States National Institutes of Health.

 

The public was clearly advised of the dangers being presented by NIAID-funded research by 2015 and 2016 when the Wuhan Institute of Virology material was being manipulated at UNC in Ralph Baric’s lab.

 

“The only impact of this work is the creation, in a lab, of a new, non-natural risk,” agrees Richard Ebright, a molecular biologist and biodefence expert at Rutgers University in Piscataway, New Jersey. Both Ebright and Wain-Hobson are long-standing critics of gain-of-function research.

 

In their paper, the study authors also concede that funders may think twice about allowing such experiments in the future. "Scientific review panels may deem similar studies building chimeric viruses based on circulating strains too risky to pursue," they write, adding that discussion is needed as to "whether these types of chimeric virus studies warrant further investigation versus the inherent risks involved”.

 

But Baric and others say the research did have benefits. The study findings “move this virus from a candidate emerging pathogen to a clear and present danger”, says Peter Daszak, who co-authored the 2013 paper. Daszak is president of the EcoHealth Alliance, an international network of scientists, headquartered in New York City, that samples viruses from animals and people in emerging-diseases hotspots across the globe.

 

Studies testing hybrid viruses in human cell culture and animal models are limited in what they can say about the threat posed by a wild virus, Daszak agrees. But he argues that they can help indicate which pathogens should be prioritized for further research attention.”(Source: https://www.nature.com/news/engineered-bat-virus-stirs-debate-over-risky-research-%201.18787 )

 

Knowing that the U.S. Department of Health and Human Services (through CDC, NIH, NIAID, and their funded laboratories and commercial partners) had patents on each proposed element of medical counter measures and their funding, Dr. Fauci, Dr. Gao (China CDC), and Dr. Elias (Bill and Melinda Gates Foundation) conspired to commit acts of terror on the global population – including the citizens of the United States – when, in September 2019, they published the following mandate:

 

“Countries, donors and multilateral institutions must be prepared for the worst. A rapidly spreading pandemic due to a lethal respiratory pathogen (whether naturally emergent or accidentally or deliberately released) poses additional preparedness requirements. Donors and multilateral institutions must ensure adequate investment in developing innovative vaccines and therapeutics, surge manufacturing capacity, broad-spectrum antivirals and appropriate non-pharmaceutical interventions. All countries must develop a system for immediately sharing genome sequences of any new pathogen for public health purposes along with the means to share limited medical countermeasures across countries.

 

Progress indicator(s) by September 2020

 

A.     Donors and countries commit and identify timelines for: financing and development of a universal influenza vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its Member States develop options for standard procedures and timelines for sharing of sequence data, specimens, and medical countermeasures for pathogens other than influenza.

 

B.      Donors, countries and multilateral institutions develop a multi-year plan and approach for strengthening R&D research capacity, in advance of and during an epidemic.

 

C.      WHO, the United Nations Children’s Fund, the International Federation of Red Cross and Red Crescent Societies, academic and other partners identify strategies for increasing capacity and integration of social science approaches and researchers across the entire preparedness/response continuum.”(Source: https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf (page 8) )

 

As if to confirm the utility of the September 2019 demand for “financing and development of” vaccine and the fortuitous SARS CoV-2 alleged outbreak in December of 2019, Dr. Fauci began gloating that his fortunes for additional funding were likely changing for the better. In a February 2020 interview in STAT, he was quoted as follows:

 

““The emergence of the new virus is going to change that figure, likely considerably, Fauci said. “I don’t know how much it’s going to be. But I think it’s going to generate more sustained interest in coronaviruses because it’s very clear that coronaviruses can do really interesting things.””(Source: https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-interest-hurt-coronavirus-research/)

 

 

18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting in death of American Citizens

Section 802 of the USA PATRIOT Act (Pub. L. No. 107-52) expanded the definition of terrorism to cover "domestic," as opposed to international, terrorism. A person engages in domestic terrorism if they do an act "dangerous to human life" that is a violation of the criminal laws of a state or the United States, if the act appears to be intended to: (i) intimidate or coerce a civilian population; (ii) influence the policy of a government by intimidation or coercion;

 

Dr. Anthony Fauci has intimidated and coerced a civilian population and sought to influence the policy of a government by intimidation and coercion.

 

With no corroboration, Dr. Anthony Fauci promoted (Source: https://www.cato.org/blog/did-mitigation-save-two-million-lives ) Professor Neil Ferguson’s computer simulation derived claims that,

 

“The world is facing the most serious public health crisis in generations. Here we provide concrete estimates of the scale of the threat countries now face.

 

“We use the latest estimates of severity to show that policy strategies which aim to mitigate the epidemic might halve deaths and reduce peak healthcare demand by two-thirds, but that this will not be enough to prevent health systems being overwhelmed. More intensive, and socially disruptive interventions will therefore be required to suppress transmission to low levels. It is likely such measures – most notably, large scale social distancing – will need to be in place for many months, perhaps until a vaccine becomes available.” (Source: https://www.imperial.ac.uk/news/196234/covid-19-imperial-researchers-model-likely-impact/)

 

Reporting to the President that as many as 2.2 million deaths may result from a pathogen that had not yet been isolated and could not be measured with any accuracy, Dr. Fauci intimidated and coerced the population and the government into reckless, untested, and harmful acts creating irreparable harm to lives and livelihoods. (Source: https://www.npr.org/2020/03/31/823916343/coronavirus-task-force-set-to-detail-the-data-that-led-to-extension-of-guideline) Neither the Imperial College nor the “independent” Institute for Health Metrics and Evaluation (principally funded by the Bill and Melinda Gates Foundation) (Source: https://www.gatesfoundation.org/Media-Center/Press-Releases/2017/01/IHME-Announcement) had any evidence of success in estimating previous burdens from coronavirus but, without consultation or peer-review, Dr. Fauci adopted their terrifying estimates as the basis for interventions that are explicitly against medical advice.

 

a.      The imposition of social distancing was based on computer simulation and environmental models with NO disease transmission evidence whatsoever.

 

b.      The imposition of face mask wearing was directly against controlled clinical trial evidence and against the written policy in the Journal of the American Medical Association.

 

“Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people from becoming ill.”(Source: https://jamanetwork.com/journals/jama/fullarticle/2762694?fbclid=IwAR2RE-c4V-fhUodui0JQRbiHRcgEJuDKG_21N4oL5zAfciQfWCyHAsetJmo)

c.      In both the Imperial College and the IHME simulations, quarantines were modeled for the sick, not the healthy.

 

  

Insisting on vaccines while blockading the emergency use of proven pharmaceutical interventions may have contributed to the death of many patients and otherwise healthy individuals.(Source: https://www.reuters.com/investigates/special-report/health-coronavirus-usa-cost/)

Using the power of NIAID during the alleged pandemic, Dr. Anthony Fauci actively suppressed proven medical countermeasures used by, and validated in scientific proceedings, that offered alternatives to the products funded by his conspiring entities for which he had provided direct funding and for whom he would receive tangible and intangible benefit.

 

 

18 U.S.C. § 1001 – Lying to Congress

Except as otherwise provided in this section, whoever, in any matter within the jurisdiction of the executive, legislative, or judicial branch of the Government of the United States, knowingly and willfully—

1. falsifies, conceals, or covers up by any trick, scheme, or device a material fact;
2. makes any materially false, fictitious, or fraudulent statement or representation; or
3. makes or uses any false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry;

shall be fined under this title, imprisoned not more than 5 years or, if the offense involves international or domestic terrorism (as defined in section 2331), imprisoned not more than 8 years, or both. If the matter relates to an offense under chapter 109A, 109B, 110, or 117, or section 1591, then the term of imprisonment imposed under this section shall be not more than 8 years.

 

On October 22, 2020, the United States Government Accountability Office (GAO) published a report entitled: BIOMEDICAL RESEARCH: NIH Should Publicly Report More Information about the Licensing of Its Intellectual Property. In this document, the authors reported that the National Institutes of Health (NIH) received, “up to $2 billion in royalties from its contributions to 34 drugs sold from 1991-2019.”(Source: https://www.gao.gov/products/GAO-21-52)

 

A casual review of the NIH Office of Technology Transfer report of active licenses (Source: https://www.ott.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics) appears to conflict with the GAO report on several important facts. Conspicuously absent from the GAO report are over 30 patents associated with active compounds generating billions of dollars in revenue. Why would it be that the GAO and the NIH couldn’t agree on something as simple as drugs generating income for NIH?

 

Since the passage of the Bayh Dole Act (Pub. L. 96-517, December 12, 1980), federally funded research has been an economic bonanza for U.S. universities, federal agencies, and their selected patronage. For the first decade following Bayh Dole, NIH funding doubled from $3.4 billion to $7.1 billion. A decade later, it doubled again to $15.6 billion. In the wake of September 2001, the National Institute for Allergy and Infectious Diseases (NIAID) saw its direct budget increase over 300%, without accounting for DARPA, funds of as much as $1.7 billion annually from 2005 forward. In 2020, NIH’s budget was over $41 billion.

 

What has become of the $763 billion of taxpayer funds allocated to making America healthier since inventors have been commercially incentivized? Who has been enriched?

 

The answer, regrettably, is that no accountability exists to answer these questions. The NIH is the named owner of at least 138 patents since 1980.

The United States Department of Health and Human Services is the named owner of at least 2,600 patents.

 

NIAID grants or collaboration have resulted in 2,655 patents and patent applications of which only 95 include an assignment to the Department of Health and Human Services as an owner. Most of these patents are assigned to universities thereby making the ultimate commercial beneficiaries entirely opaque. One of the largest holders is SIGA Technologies (NASDAQ: SIGA) who, while publicly reporting close affiliation with NIAID, is not referenced in the NIH GAO report. SIGA’s CEO, Dr. Phillip L. Gomez spent 9 years at NIAID developing its vaccine program for HIV, SARS, Ebola, West Nile Virus, and Influenza before exiting to commercial ventures. While their technology is clearly derived from NIAID science, the company reports revenue from NIAID but no royalty or commercial payments to NIH or any of its programs.

  

NIAID’s Director, Dr. Anthony Fauci, is listed as an inventor on 8 granted U.S. patents. None of them are reported in NIAID, NIH, or GAO reports of active licensing despite the fact that Dr. Fauci reportedly was compelled to get paid for his interleukin-2 “invention” – payments he reportedly donated to an unnamed charity. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545012/)

 

Of the 21 patents listed in the U.S. Food and Drug Administration’s (FDA) Orange book, itemized in the GAO report, none of Dr. Anthony Fauci’s patents are listed. Furthermore, none of the NIAID patents are listed despite clear evidence that Gilead Sciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) have generated over $2 billion annually from sales that were the direct result of NIAID funded science. Missing from the GAO report are 2 patents for Velclade® which has been generating sales in excess of $2.18 billion annually for several years. None of the patents for Yescarta® are listed in the GAO report. None of the Lumoxiti® patents are listed in the GAO report. None of the Kepivance® patents are listed in the GAO report. In violation of 37 USC §410.10 and 35 USC §202(a), over 13 of the 21 patents in the GAO report fail to disclose government interest despite being the direct result of NIH funding.

 

Dr. Anthony Fauci’s Own Patent Track Record:

 

US Patent 6,190,656 and 6,548,055 - Immunologic enhancement with intermittent interleukin-2 therapy:

 

A method for activating a mammalian immune system entails a series of IL-2 administrations that are affected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T-cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is affected by delivering a genetically engineered retroviral vector directly to the patient.

 

This application is a continuation of U.S. patent application Ser. No. 08/487,075, filed Jun. 7, 1995, now abandoned, which is a continuation in part of U.S. patent application Ser. No. 08/063,315, filed May 19, 1993, now issued as U.S. Pat. No. 5,419,900, and U.S. patent application Ser. No. 08/452,440, filed May 26, 1995, now issued as U.S. Pat. No. 5,696,079, which is the National Stage filed under 35 USC 371 of PCT/US94/05397, filed May 19, 1994, the contents of which are incorporated herein by reference.

 

Filed May 19, 1993

 

Issued a Final Rejection January 20, 1998. Rejected after abandonment August 14, 1998 and April 12, 1999. Reduced and modified claims granted May 8, 2000.

 

This family of patents was the basis of Fauci’s lie to the British Medical Journal in which he falsely stated:

 

“Dr Anthony Fauci told the BMJ that as a government employee he was required by law to put his name on the patent for the development of interleukin 2 and was also required by law to receive part of the payment the government received for use of the patent. He said that he felt it was inappropriate to receive payment and donated the entire amount to charity.”

 

            US Patent 6,911,527 - HIV related peptides:

 

This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.

 

Filed May 6, 1999

 

Rejected as unpatentable January 22, 2003. Issued with a final rejection on July 15, 2004 after submitting reconsideration requests. Modified and restricted claims allowed September 29, 2004.

 

US Patent 7,368,114 - Fusion protein including of CD4:

 

Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.

 

Filed October 24, 2002

 

Rejected as unpatentable August 18, 2006. Paid appeal to overturn examiner’s findings February 15, 2007. Rejected again May 11, 2007. On October 10, 2007 applicants further narrowed the construction of what was clearly not a patent and the USPTO granted less than half the claims that had been sought in the original filing.

 

 

US Patent 9,896,509, 9,193,790 and 9,441,041 - Use of antagonists of the interaction between HIV GP120 and .alpha.4.beta.7 integrin:

 

Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist, thereby treating the HIV infection. In several examples, the .alpha.4 integrin antagonist is a monoclonal antibody that specifically binds to a .alpha.4, .beta.1 or .beta.7 integrin subunit, or a cyclic hexapeptide, with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

 

Rejected May 22, 2017 as Double Patenting. In their response, the applicants acknowledge the illegal act and seek only those components of their application that extend beyond the life of the issued patents. On October 11, 2017, the limited claims were issued.

 

A sample of the convoluted flow of funds that evades public disclosure.

 

U.S. Patent 8,999,351 was issued to Tekmira Pharmaceuticals Corporation in Burnaby, British Columbia. In their patent, they disclose that their research was supported by a grant from the National Institute of Allergy and Infectious Disease (Grant HHSN266200600012C). Ironically, this $23 million grant was awarded in 2006 to Alnylam Pharmaceuticals, Inc., not to Tekmira.(Source: Alnylam Awarded $23 Million U.S. Government Contract to Develop RNAi Therapeutics | Technology Networks)

 

 

In 2012, Alnylam agreed to pay Tekmira $65 million to settle legal disputes including a $1 billion damages claim for “relentless and egregious” misappropriation of Tekmira’s trade secrets. From the patent filing’s earliest priority of November 10, 2008, there is no public record stating Tekmira as the beneficiary of this NIAID grant. Notwithstanding, the lipid nanoparticle technology developed from this grant is the technology now used in the Moderna COVID-19 intervention. In their 10-Q filing, Alnylam reports to have a license to technology from Arbutus – formerly Tekmira – which has accused Acuitas of misappropriating trade secrets and licensing them to Moderna and Pfizer’s collaboration with BioNTech.

 

Additional references can be found at:

 

https://www.ott.nih.gov/nih-and-its-role-technology-transfer https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206288Orig1s000TAltr.pdf https://www.gao.gov/assets/720/710287.pdf https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%22

 

 

15 U.S.C. §1-3 – Conspiring to Criminal Commercial Activity

 

Every contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce among the several States, or with foreign nations, is declared to be illegal. Every person who shall make any contract or engage in any combination or conspiracy hereby declared to be illegal shall be deemed guilty of a felony, and, on conviction thereof, shall be punished by fine not exceeding $100,000,000 if a corporation, or, if any

other person, $1,000,000, or by imprisonment not exceeding 10 years, or by both said punishments, in the discretion of the court.

 

The National Institute of Health’s grant AI23946-08 issued to Dr. Ralph Baric at the University of North Carolina at Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.(Source: U.S. Provisional Application No. 60/206,537, filed May 21, 2000) In one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.

 

“Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones.”(Source: https://www.pnas.org/content/100/22/12995)

 

On April 19, 2002, the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first public record of the claims, they sought to patent a means of producing, “an infectious, replication defective, coronavirus.” This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 before SARS was ever detected in humans.

 

Against this backdrop, we noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003 SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Work associated with this virus by their select collaborators included considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment (both vaccine and therapeutic intervention), and weaponization inquiries.

 

In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852 patent (Claim 1), no research in the United States could be conducted without permission or infringement.

 

We noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research grants from several federal agencies but also sat on the World Health Organization’s International Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for determining “novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the form of new research funding authorizations and associated patenting and commercial collaboration. Together with CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of interests constituted what we would suggest are “interlocking directorates” under U.S. anti-trust laws.

 

 

 

·        1986-1990    NIAID Grant AI 23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant Coronavirus” Filed 2002 and issued 2007 https://patents.google.com/patent/US7279327B2/ru

The paper first published from the NIAID grant is https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf

 

·        1990    Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on coronavirus November 14, 2000 which was abandoned April 2010 making it public domain.

 

·        1990s    Work focused on CoV association with cardiomyopathy (see above)

Early reference to the “emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf

 

·        2000    Ralph Baric AI23946 and GM63228 from the National Institutes of Health actively working recombinant CoV

 

·        2001    National Institute of Health, Allergy and Infectious diseases. “Reverse Genetics with a Coronavirus Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI

 

·        2002    Asia CoV SARS outbreak

 

·        2003    April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus.

Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand Challenges Scientific Advisory Board (served through 2010).

 

·        April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163 https://www.sbir.gov/node/305319

 

·        July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https://patents.google.com/patent/US7618802B2

Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS CoV. This research is supported by several NIH grants including National Institutes of Health Grants A128785, A148436, and A1053822.

 

·        2004    January 6, 2004 – SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators. https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706

At this conference, the term “The New Normal” was introduced by Merck

 

FAUCI AND BARIC start making money!!! National Institutes of Health, Allergy and Infectious Diseases. SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic mouse model for SARS-CoV infection.

 

National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million

 

·        November 22, 2004    University of Hong Kong patents SARS associated spike protein on CoV and pursues patent US 7,491,489

 

·        2005    DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling Technologies, June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker

 

Review timeline from https://www.youtube.com/watch?v=rO_EeYB0i0U and https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf

 

·        2008    Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC Chapel Hill https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104

 

·        2009    Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant from NIAID)

 

·        2010    Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID)

Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued patents.

 

·        August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164 which attracted the investment of (and “inventorship” for) venture capitalists at Flagship Ventures. This patent grew out of the work of Dr. Jason P. Schrum of Harvard Medical School supported by National Science Foundation Grant #0434507. While the application claims priority to August 2010, the application didn’t get finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final rejection on this original patent rejecting all claims.

https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with reference to the grant funding in https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf

 

 

·        2011    Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all of its SARS technology.

 

Biodefense Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill (non-competitive grant from NIAID)

 

·        2012    MERS isolated in Egypt

 

Biodefense Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive grant from NIAID)

 

·        2013    Biodefense Grant U54 AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant from NIAID)

 

·        2014    April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435

 

·        2015    Moderna signs a vaccine development agreement with NIAID and executes it with the lead on the mRNA-1273 lead developer and inventor Guiseppe Ciaramella. https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html

 

·        2016    NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is used in tandem with) Moderna’s technology. https://patents.google.com/patent/WO2018081318A1/en Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS

CoV-2 according to Moderna’s report here (“In January 2020, once it was discovered that the infection in Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic sequence for the virus.”) https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html

In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the Chinese government filed in Australia in 2013 https://patents.google.com/patent/AU2014231357A1/en?inventor=Jason+MCLELLAN.

 

·        2017    August – Sanofi buys Protein Science Corp with considerable SARS patent holdings

·        2018    June – Sanofi buys Ablynx with considerable SARS patent holdings

·        2019    March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create- affordable-molecular-diagnostics/ funded by Open Philanthropy – the same organization that would be the financial sponsor of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan in October 2019.

 

 

 

 

15 U.S.C. §8 – Market Manipulation and Allocation

Every combination, conspiracy, trust, agreement, or contract is declared to be contrary to public policy, illegal, and void when the same is made by or between two or more persons or corporations, either of whom, as agent or principal, is engaged in importing any article from any foreign country into the United States, and when such combination, conspiracy, trust, agreement, or contract is intended to operate in restraint of lawful trade, or free competition in lawful trade or commerce, or to increase the market price in any part of the United States of any article or articles imported or intended to be imported into the United States, or of any manufacture into which such imported article enters or is intended to enter. Every person who shall be engaged in the importation of goods or any commodity from any foreign country in violation of this section, or who shall combine or conspire with another to violate the same, is guilty of a misdemeanor, and on conviction thereof in any court of the

United States such person shall be fined in a sum not less than $100 and not exceeding $5,000, and shall be further punished by imprisonment, in the discretion of the court, for a term not less than three months nor exceeding twelve months.

 

Through non-competitive grant awards to UNC Chapel Hill’s Ralph Baric, to selection of the Bio-Safety Level 4 laboratory locations, to the setting of prices for Remdesivir and mRNA therapies from Moderna and Pfizer, NIAID, CDC, and the U.S. Department of Health and Human Services have been involved in allocating Federal funds to conspiring parties without independent review.

 

Around March 12, 2020, in an effort to enrich their own economic interests by way of securing additional funding from both Federal and Foundation actors, the CDC and NIAID’s Dr Fauci elected to suspend testing and classify COVID-19 by capricious symptom presentation alone. Forcing the public to rely on The COVID Tracking Project – funded by the Bloomberg, Zuckerberg and Gates Foundation and presented by a media outlet (The Atlantic) – not a public health agency – Dr. Fauci used fraudulent testing technology (RT-PCR) to conflate “COVID cases” with positive PCR tests in the living while insisting that COVID deaths be counted by symptoms alone. This perpetuated a market demand for his desired vaccine agenda which was recited by him and his conspiring parties around the world until the present. Not surprisingly, this was necessitated by the apparent fall in cases that constituted Dr. Fauci’s and others’ criteria for depriving citizens of their 1st Amendment rights.

 

 

15 U.S.C. § 19 – Interlocking Directorates

No person shall, at the same time, serve as a director or officer in any two corporations (other than banks, banking associations, and trust companies) that are—

1. engaged in whole or in part in commerce; and
2. by virtue of their business and location of operation, competitors, so that the elimination of competition by agreement between them would constitute a violation of any of the antitrust laws; if each of the corporations has capital, surplus, and undivided profits aggregating more than $10,000,000 as adjusted pursuant to paragraph (5) of this subsection.

 

 

Dr. Fauci is on the Leadership Council of the Bill and Malinda Gates Global Vaccine Action Plan

 

Dr. Fauci while controlling the economic dispensation of Federal research funding, Dr. Fauci has been, and continues to be, on the World Health Organization’s Global Preparedness Monitoring Board. He is joined on this board by the conflicted donor from the Bill and Melinda Gates Foundation’s Dr. Chris Elias and the State Council of China’s Dr. George

F. Gao of the Chinese CDC. This GPMB stipulated that all member states must take part in a global simulation of the release of a respiratory pathogen.

 

Dr. Baric is one of the primary beneficiaries of U.S. Federal funds, runs a BSL-4 facility and sits on the International Committee on Taxonomy of Virus Coronaviridae Working Group tasked to confirm the presence of absence of the pathogen for which he is directly compensated.

 

As referenced in the section covering violations of 18 U.S.C. § 1001 above, numerous undisclosed commercial relationships exist between funded researchers, their funding agencies, and commercial interests in which disclosed and undisclosed commercial terms exist. A complete list of all potential implicated parties is listed in the section below entitled “The Commercial Actors”.

 

It appears that during the period of patent enforcement and after the Supreme Court ruling confirming that patents on genetic material were illegal, the CDC and National Institute of Allergy and Infectious Diseases led by Anthony Fauci (hereinafter “NIAID” and "Dr Fauci", respectively) entered into trade among States (including, but not limited to working with Ecohealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent rights.

 

It further appears that during the period of patent enforcement and after the Supreme Court ruling confirming that patents on genetic material was illegal, the CDC and National Institute of Allergy and Infectious Diseases (hereinafter “NIAID”) entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016.

 

It further appears that during the period of patent enforcement and after the Supreme Court ruling confirming that patents on generic material was illegal, the CDC and NIAID entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations to conduct chimeric construction of novel coronavirus material with specific virulence properties prior to, during, and following the determination made by the National Institutes for Health in October 17, 2014 that this work was not sufficiently understood for its biosecurity and safety standards.

 

In this inquiry, it is presumed that the CDC and its associates were: a) fully aware of the work being performed using their patented technology; b) entered into explicit or implicit agreements including licensing, or other consideration; and, c) willfully engaged one or more foreign interests to carry forward the exploitation of their proprietary technology when the U.S. Supreme Court confirmed that such patents were illegal and when the National Institutes of Health issued a moratorium on such research.

 

Reportedly, in January 2018, the U.S. Embassy in China sent investigators to Wuhan Institute of Virology and found that, “During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory.” The Washington Post reported that this information was contained in a cable dated 19 January 2018. Over a year later, in June 2019, the CDC conducted an inspection of Fort Detrick’s U.S. Army Medical Research Institute of Infectious Diseases (hereinafter “USAMRIID”) and ordered it closed after alleging that their inspection found biosafety hazards. A report in the journal Nature in 2003 (423(6936): 103) reported cooperation between CDC and USAMRIID on coronavirus research followed by considerable subsequent collaboration. The CDC, for what appear to be the same type of concern identified in Wuhan, elected to continue work with the Chinese government while closing the U.S. Army facility.

 

The CDC reported the first case of SARS-CoV like illness in the United States in January 2020 with the CDC’s Epidemic Intelligence Service reporting 650 clinical cases and 210 tests. Given that the suspected pathogen was first implicated in official reports on December 31, 2019, one can only conclude that CDC: a) had the mechanism and wherewithal to conduct tests to confirm the existence of a “novel coronavirus”; or, b) did not have said mechanism and falsely reported the information in January. It tests credulity to suggest that the WHO or the CDC could manufacture and distribute tests for a “novel” pathogen when their own subsequent record on development and deployment of tests has been shown to be without reliability.

 

35 U.S.C. §200 - 206 – Disclosure of Government Interest

35 U.S.C. §202 (c)(6)

 

An obligation on the part of the contractor, in the event a United States patent application is filed by or on its behalf or by any assignee of the contractor, to include within the specification of such application and any patent issuing thereon, a statement specifying that the invention was made with Government support and that the Government has certain rights in the invention.

 

Over 5000 patents and patent applications have included reference to SARS Coronavirus dating back to priority dates of 1998. They are summarized below.

 

 

On July 23, 2020, the Patent Trial and Appeal Board of the United States Patent and Trademark Office rejected Moderna’s efforts to invalidate U.S. Patent 8,058,069. This patent, owned by Arbutus Biopharma Corp (principally owned by Roivant Science Ltd), covers the lipid nanoparticle (LNP) required to deliver an mRNA vaccine. Some of the core technology was based on work originally done at the University of British Columbia and was first licensed in 1998.

 

mRNA-1273 – the experimental vaccine developed by Moderna for COVID-19 – uses the LNP technology that Moderna thought it had licensed from Acuitas Therapeutics Inc., a firm developed by a former principal of Arbutus’ prior company Tekmira. That license did not authorize Moderna to use the technology for the COVID-19 vaccine.

 

M·CAM and Knowledge Ecology International have independently confirmed that Moderna has violated U.S. law in failing to disclose the U.S. government’s funding interest in their patents and patent applications. While this negligence impacts all of Moderna’s over 130 granted U.S. patents, it is particularly problematic for U.S. Patent 10,702,600 (‘600) which is the patent relating to, “a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle.” The specific claims addressing the pivot to the SARS Coronavirus were patented on March 28, 2019 – 9 months before the SARS CoV-2 outbreak! Both the patent and the DARPA funding for the technology were disclosed in scientific publication (New England Journal of Medicine) but the government funds were not acknowledged in the patent.

 

In 2013, the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program awarded grant funding to Moderna Therapeutics for the development of a new type of vaccine based on messenger RNA. The initial DARPA grant was W911NF-13-1-0417. The company used that technology to develop its COVID-19 vaccine, currently undergoing clinical trials in conjunction with NIH.(Source: https://crsreports.congress.gov/product/pdf/IN/IN11446)

 

Under the Federal Acquisition Regulation (FAR) rules, contractor to the Federal Government must provide information regarding intellectual property infringement issues as part of their contract. Under FAR §27.201-1(c) and (d), the Government both requires a notice of infringement or potential infringement as well as retention of economic liability for patent infringements. Specifically, in FAR §52.227.3 (a), the “Contractor shall indemnify the Government and its officers, agents, and employees against liability, including costs for infringement of any United States Patent…”. In addition to the patents cited by the USPTO in their examination of ‘600, M·CAM has identified fourteen other issued patents preceding the ‘600 patent which were used by patent examiners to limit patents arising from the same funded research including patents sought by CureVac.

 

In short, while Moderna enjoys hundreds of millions of dollars of funding, allegiance, and advocacy from Anthony Fauci and his NIAID, since its inception, it has been engaged in illegal patent activity and demonstrated contempt for U.S. Patent law. To make matters worse, the U.S. Government has given it financial backing in the face of undisclosed infringement risks potentially contributing to the very infringement for which they are indemnified.

 

 

21 C.F.R. § 50.24 et seq., Illegal Clinical Trial

 

It is unlawful to conduct medical research (even in the case of emergency) without a series of steps taken to:

1. Establish the research with a duly authorized and independent institutional review board;
2. Secure informed consent of all participants including a statement of risks and benefits; and,
3. Engage in consultation with the community in which the study is to be conducted.

 

Dr. Anthony Fauci has forced upon the healthy population of the United States an unlawful clinical trial in which the U.S. Department of Health and Human Services are extrapolating epidemiologic data. No informed consent has been sought or secured for any of the “medical countermeasures” forced upon the population and no independent review board – as defined by the statute – has been empaneled.

 

Through April 2020, the official recommendation by the Journal of the American Medical Association was unambiguous.

 

“Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people from becoming ill.”(Source: Medical Masks | Infectious Diseases | JAMA | JAMA Network)

 

Part of that lack of evidence in fact showed that cloth facemasks actually increased influenza-linked illness. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420971/)

 

In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a “belief” that face masks limit the spread of SARS CoV-2. To date, not a single study has confirmed that a mask prevented the transmission of, or the infection by SARS CoV-2.

 

All parties mandating the use of facemasks are not only willfully ignoring established science but are engaging in what amounts to a whole population clinical trial. This conclusion is reached by the fact that facemask use and COVID-19 incidence are being reported in scientific opinion pieces promoted by the United States Centers for Disease Control and Prevention and others.(Source: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html)

 

Social distancing of up to 6 feet has been promoted as a means of preventing person-to-person transmission of influenza-like viruses. While one study hypothesized that infection could happen in a 6 foot range, the study explicitly states that person-to-person transfer was not tested and viability of the virus at 6 feet was not even a subject of the investigation.(Source: Werner E. Bischoff, Katrina Swett, Iris Leng, Timothy R. Peters, Exposure to Influenza Virus Aerosols During Routine Patient Care, The Journal of Infectious Diseases, Volume 207, Issue 7, 1 April 2013, Pages 1037–1046, https://doi.org/10.1093/infdis/jis773) That did not stop the misrepresentation of the study to be used as the basis for an unverified medical counter measure of social distancing. To date, no study has established the efficacy of social distancing to modify the transmission of SARS CoV-2. Public health officials have referenced:

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907354/#CR43

 

In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a “belief” that social distancing of a healthy population limits the spread of SARS CoV-2. To date, not a single study has confirmed that social distancing of any population prevented the transmission of, or the infection by SARS CoV-2.

It is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product or service can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well- controlled human clinical studies, substantiating that the claims are true at the time they are made. As a result, every party promoting the use of face masks is violating the FTC Act.

 

 

 

The Commercial Actors

SARS coronavirus is a new topic for many individuals. Since 1999, the ability to manipulate and exploit coronavirus for a variety of purposes has attracted the attention of individuals, institutions and commercial organizations in public, private, and not-for-profit sectors.

The following is a list of over 4,000 patents and patent applications filed for the express purpose of controlling some aspect of the SARS coronavirus.

PATENT	Title	Owner	Priority	File Date	Issue Date
US9995706	Amperometric gas sensor	Steris Corporation	25- Jun- 12	30- Sep -14	12- Jun- 18
US9995705	Amperometric gas sensor	Steris Corporation	25- Jun- 12	30- Sep -14	12- Jun- 18
US9994558	Multicyclic compounds and methods of using same	Karyopharm Therapeutics Inc.	20- Sep- 13	19- Sep -14	12- Jun- 18
US9994550	Heterocyclic modulators of lipid synthesis for use against cancer and viral infections	3-V Biosciences, Inc.	7- Jan- 14	7- Jan -15	12- Jun- 18
US9993543	Immunogenic compositions comprising silicified virus and methods of use	Portland State University	31- Jan- 13	31- Jan -14	12- Jun- 18
US9982257	Chiral control	WAVE LIFE SCIENCES LTD.	13- Jul-12	12- Jul- 13	29- May -18
US9982241	Recombinant HCMV and RHCMV vectors and uses thereof	Oregon Health & Science University	14- May- 10	1- Oct -15	29- May -18
US9982025	Monomeric griffithsin tandemers	The United States of America, as represented by the Secretary, Department of Health and Human Services	5- Jun- 13	5- Jun -14	29- May -18
US9981036	Compositions, comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	12- Dec- 11	26- Feb -16	29- May -18
US9975885	Broad-spectrum non-covalent coronavirus protease inhibitors	PURDUE RESEARCH FOUNDATION	28- Apr- 16	28- Apr -17	22- May -18
US9974850	Immunogenic compositions and uses thereof	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	25- Mar- 15	25- Mar -16	22- May -18
US9974848	Tetanus toxoid and CCL3 improve DC vaccines	Duke University	14- Nov- 13	14- Nov -14	22- May -18
US9974845	Combination of vaccination and inhibition of the PD-1 pathway	CureVac AG	22- Feb- 13	21- Feb -14	22- May -18
US9970061	Bioagent detection oligonucleotides	IBIS BIOSCIENCES, INC.	27- Dec- 11	27- Dec -12	15- May -18
US9969793	Compositions and methods for the treatment of immunodeficiency	ADMA Biologics, Inc.	28- Oct- 14	13- Nov -17	15- May -18
US9963718	LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus- producing cells for the therapy of tumors	VIRATHERAPEUTICS GMBH	8- Oct- 08	7- Apr -17	8- May -18
US9963611	Composition for use in decreasing the transmission of human pathogens	Innonix Technologies, Incorporated	29- May- 09	21- May -10	8- May -18
US9963427	Dithiol mucolytic agents	PARION SCIENCES, INC.	23- Aug- 13	11- Mar -16	8- May -18
US9962439	Injectable vaccine composition	NITTO DENKO CORPORATION	3- Oct- 13	2- Oct -14	8- May -18
US9957302	Treating cancer with viral nucleic acid	Mayo Foundation for Medical Education and Research	20- Feb- 07	6- Jul- 15	1- May -18
US9957300	Virus-like particles, methods of preparation, and immunogenic compositions	Emory University	17- May- 02	4- May -15	1- May -18
US9957238	Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds	Parion Sciences, Inc.	13- Dec- 13	1- Mar -17	1- May -18
US9951317	Highly efficient influenza matrix (M1) proteins	NOVAVAX, INC.	11- Jul-03	6- Oct -16	24- Apr- 18
US9951124	Antibody producing non-human mammals	MERUS N.V.	27- Jun- 08	25- Jan -13	24- Apr- 18
US9951122	Antibodies against influenza virus and methods of use thereof	BURNHAM INSTITUTE FOR MEDICAL RESEARCH	6- Dec- 07	12- Aug -13	24- Apr- 18
US9950062	Compounds and compositions as TLR activity modulators	GLAXOSMITHKLINE BIOLOGICALS SA	2- Sep- 09	1- Sep -10	24- Apr- 18
US9945856	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics	AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V.	18- Aug- 03	13- Aug -14	17- Apr- 18
US9945780	Use of a fluorescent material to detect failure or deteriorated performance of a fluorometer	GEN-PROBE INCORPORATED	14- Jun- 12	7- Jun -13	17- Apr- 18
US9944928	Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositions	York Yuan Yuan Zhu	23- Jul-07	2- Jul- 15	17- Apr- 18
US9944695	Antibody producing non-human mammals	Merus N.V.	27- Jun- 08	30- Apr -14	17- Apr- 18
US9944686	Treatment of tumors with recombinant interferon alpha	SUPERLAB FAR EAST LIMITED	28- Feb- 01	5- Sep -13	17- Apr- 18
US9944649	Compounds and compositions as toll-like receptor 7 agonists	Novartis Ag	1- May- 14	29- Apr -15	17- Apr- 18
US9943614	Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods	BRIGHAM YOUNG UNIVERSITY	17- Jun- 08	16- Jun -09	17- Apr- 18
US9938300	Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors	Forma Therapeutics, Inc.	5- Feb- 15	4- Feb -16	10- Apr- 18
US9938275	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	18- Jun- 04	23- Jan -17	10- Apr- 18
US9938258	Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof	Karyopharm Therapeutics Inc.	29- Nov- 12	27- Nov -13	10- Apr- 18
US9932351	Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors	Forma Therapeutics, Inc.	5- Feb- 15	4- Feb -16	3- Apr- 18
US9932323	Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones	Rutgers, The State University of New Jersey	11- Sep- 12	13- Jan -17	3- Apr- 18
US9931316	Antiviral activity from medicinal mushrooms and their active constituents	Not Available	31- Mar- 15	14- Sep -15	3- Apr- 18
US9926340	NAD analogs and methods of using said NAD analogs in determining ribosylation of proteins with PARP mutants	Biolog Life Science Institute Forshungslabor und Biochemica-Vertrieb GmbH	8- Apr- 15	1- Apr -16	27- Mar -18
US9925215	Anionically modified polyallylamine derivative, use of anionically modified polyallylamine derivative as medicine, particularly for propylaxis and treatment of infections of respiratory tract caused by human metapneumovirus (hMPV), human rhinoviruses (HRV), and infection by influenza virus type A (IAV) and pharmaceutical composition comprising the anionically modified polyallylamine derivative	UNIWERSYTET JAGIELLONSKI	29- Jul-14	25- Oct -17	27- Mar -18
US9920314	Compositions for and methods of identifying antigens	President and Fellows of Harvard College	21- Feb- 06	6- May -15	20- Mar -18
US9920128	Synthetic antiserum for rapid-turnaround therapies	The Johns Hopkins University	28- Jan- 15	20- Jan -16	20- Mar -18
US9919034	Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V	TAMIR BIOTECHNOLOGY, INC.	28- Mar- 14	10- Jun -15	20- Mar -18
US9915613	Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector	GEN-PROBE INCORPORATED	24- Feb- 11	21- Mar -14	13- Mar -18
US9914976	Methods and compositions for prostate cancer metastasis	FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FA	25- Mar- 11	27- May -16	13- Mar -18
US9913801	Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione	YOUR ENERGY SYSTEMS, LLC	15- Feb- 13	15- Mar -13	13- Mar -18
US9909176	Efficient deep sequencing and rapid genomic speciation of RNA viruses (vRNAseq)	The Johns Hopkins University	8- Sep- 14	1- Sep -15	6- Mar -18
US9908946	Generation of binding molecules	Merus N.V.	26- Sep- 11	16- Sep -15	6- Mar -18
US9908675	Powdered pouch and method of making same	MONOSOL, LLC	16- Apr- 12	19- Jul- 16	6- Mar -18

US9907796	Methods of treating tumoral diseases, or bacterial or viral infections	INHIBIKASE THERAPEUTICS, INC.	4- Oct- 12	15- Sep -16	6- Mar -18
US9895692	Sample-to-answer microfluidic cartridge	Micronics, Inc.	29- Jan- 10	5- Aug -15	20- Feb -18
US9895411	Analogs of C5a and methods of using same	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	29- Jun- 10	29- Jun -11	20- Feb -18
US9895341	Inflammation and immunity treatments	Ocean Spray Cranberries, Inc.	1- Apr- 11	30- Mar -12	20- Feb -18
US9894888	Transgenic immunodeficient mouse expressing human SIRP-alpha	INSTITUT PASTEUR	26- Mar- 12	26- Mar -13	20- Feb -18
US9890419	Nanoreporters and methods of manufacturing and use thereof	NanoString Technologies, Inc.	23- Dec- 05	20- May -16	13- Feb -18
US9890408	Multiple displacement amplification	IBIS BIOSCIENCES, INC.	15- Oct- 09	15- Oct -10	13- Feb -18
US9890362	Compositions, methods and uses for inducing viral growth	Takeda Vaccines, Inc.	5- Dec- 08	19- Sep -14	13- Feb -18
US9890361	Methods for increasing the infectivity of viruses utilizing alkyne- modified fatty acids	LIFE TECHNOLOGIES CORPORATION	26- Jan- 12	25- Jan -13	13- Feb -18
US9890206	H1N1 flu virus neutralizing antibodies	Medigen Biotechnology Corporation	20- Aug- 15	20- Aug -15	13- Feb -18
US9890169	Triazolinone compounds as HNE inhibitors	CHIESI FARMACEUTICI S.P.A.	14- Dec- 15	12- Dec -16	13- Feb -18
US9890124	Benzazepine sulfonamide compounds	Hoffmann-La Roche Inc.	15- Dec- 15	14- Jun -17	13- Feb -18
US9889194	Immunogenic composition for MERS coronavirus infection	New York Blood Center, Inc.	1- Mar- 13	28- Feb -14	13- Feb -18
US9885092	Materials and methods for detection of HPV nucleic acids	QIAGEN GAITHERSBURG INC.	24- Feb- 11	23- Feb -12	6- Feb -18
US9885082	Embodiments of a probe and method for targeting nucleic acids	University of Idaho	19- Jul-11	19- Jul- 12	6- Feb -18
US9885037	Chiral control	WAVE LIFE SCIENCES LTD.	13- Jul-12	12- Jul- 13	6- Feb -18
US9884895	Methods and compositions for chimeric coronavirus spike proteins	The University of North Carolina at Chapel Hill	20- Mar- 14	20- Mar -15	6- Feb -18
US9884876	Anti-viral compounds, pharmaceutical compositions, and methods of use thereof	Kineta, Inc.	9- May- 14	8- May -15	6- Feb -18
US9884129	Release of agents from cells	The Brigham and Women's Hospital, Inc.	15- Oct- 09	5- Jan -15	6- Feb -18
US9884032	Esters of short chains fatty acids for use in the treatment of immunogenic disorders	PROPONENT BIOTECH GMBH	3- Oct- 12	3- Mar -16	6- Feb -18
US9884026	Modular particles for immunotherapy	YALE UNIVERSITY	1- Nov- 13	31- Oct -14	6- Feb -18
US9880151	Method of determining, identifying or isolating cell-penetrating peptides	Phylogica Limited	23- May- 11	23- May -12	30- Jan- 18
US9879026	Substituted spirocycles	Boehringer Ingelheim International GmbH	12- Sep- 14	29- Nov -16	30- Jan- 18
US9879003	Host targeted inhibitors of dengue virus and other viruses	Dana-Farber Cancer Institute, Inc.	11- Apr- 12	15- Mar -13	30- Jan- 18
US9878988	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases	PARION SCIENCES, INC.	29- May- 12	5- Jan -16	30- Jan- 18
US9873678	Chemical compounds	AstraZeneca AB	18- Mar- 14	17- Mar -15	23- Jan- 18
US9873674	C-Rel inhibitors and uses thereof	CORNELL UNIVERSITY	21- Sep- 12	19- Sep -13	23- Jan- 18
US9872900	Nucleic acid vaccines	ModernaTX, Inc.	23- Apr- 14	5- Apr -16	23- Jan- 18
US9872898	Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome	Ohio State Innovation Founation	24- Apr- 12	3- Oct -16	23- Jan- 18
US9872895	TLR5 ligands, therapeutic methods, and compositions related thereto	Emory University	24- Sep- 10	20- Sep -11	23- Jan- 18
US9868952	Compositions and methods for “resistance-proof†SiRNA therapeutics for influenza	Sirnaomics, Inc.	8-Jul- 12	7- Jul- 13	16- Jan- 18
US9868740	Pyrimidinone compounds which are HNE inhibitors	CHIESI FARMACEUTICI S.p.A.	12- Jun- 14	12- Jun -14	16- Jan- 18
US9868736	Deubiquitinase inhibitors and methods for use of the same	THE REGENTS OF THE UNIVERSITY OF MICHIGAN	10- Oct- 13	10- Oct -14	16- Jan- 18
US9867882	Carbohydrate conjugates as delivery agents for oligonucleotides	Alnylam Pharmaceuticals, Inc.	4- Dec- 07	25- Aug -15	16- Jan- 18
US9867877	Methods for preparing squalene	NOVARTIS AG	12- May- 10	22- Nov -16	16- Jan- 18
US9862706	Compounds	CHIESI FARMACEUTICI S.p.A.	31- May- 16	26- May -17	9- Jan- 18
US9861614	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	9- May- 12	23- Jun -15	9- Jan- 18
US9856254	Alkoxy substituted imidazoquinolines	3M Innovative Properties Company	3- Oct- 03	13- Jun -16	2- Jan- 18
US9856241	Substituted benzofuranyl and benzoxazolyl compounds and uses thereof	Karyopharm Therapeutics Inc.	3-Jul- 13	3- Jul- 14	2- Jan- 18
US9856228	Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors	PROZYMEX A/S	9- Sep- 13	8- Sep -14	2- Jan- 18
US9856224	Stable sodium channel blockers	PARION SCIENCES, INC.	30- Jun- 14	30- Jan -17	2- Jan- 18
US9855287	Anti-viral azide containing compounds	LIFE TECHNOLOGIES CORPORATION	28- Jul-10	20- Aug -15	2- Jan- 18
US9855284	Pharmaceutical compositions and methods	Pop Test Oncology LLC	3- Aug- 15	6- Dec -16	2- Jan- 18
US9849143	Broad spectrum antiviral and methods of use	The Burlington HC Research Group, Inc.	17- Apr- 06	16- Feb -17	26- Dec -17
US9845342	Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria	Spogen Biotech Inc.	17- Sep- 14	17- Sep -15	19- Dec -17
US9840731	Preservation of biological materials in non-aqueous fluid media	Gentegra, LLC	14- Mar- 13	14- Mar -14	12- Dec -17
US9840719	Variant AAV and compositions, methods and uses for gene transfer to cells, organs and tissues	The Children's Hospital of Philadelphia	22- Jul-13	22- Jul- 14	12- Dec -17
US9840491	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5- Feb- 15	4- Feb -16	12- Dec -17
US9839687	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule	SUZHOU M-CONJ BIOTECH CO., LTD.	15- Jul-15	15- Jul- 15	12- Dec -17
US9834812	Probe kit for detecting a single strand target nucleotide sequence	Fondazione Istituto Italiano Di Tecnologia	27- Dec- 12	27- Dec -13	5- Dec -17
US9834791	CRISPR-related methods and compositions with governing gRNAS	Editas Medicine, Inc.	7- Nov- 13	7- Nov -14	5- Dec -17
US9834757	Hand, foot, and mouth vaccines and methods of manufacture and use thereof	Takeda Vaccines, Inc.	7- Nov- 14	6- Nov -15	5- Dec -17
US9834595	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases	Ablynx N.V.	5- Jun- 08	29- Oct -15	5- Dec -17
US9833504	Virus-like particles and process for preparing same	Folia Biotech Inc.	13- May- 11	1- May -12	5- Dec -17
US9833492	Combinations of a caspase inhibitor and an antiviral agent	Centre National de la Recherche Scientifique	2- Nov- 07	15- May -15	5- Dec -17
US9832998	Antiviral compositions	Long Island University	30- May- 07	19- Mar -15	5- Dec -17
US9828382	Pyrimidinone compounds as human neutrophil elastase inhibitors	Chiesi Farmaceutici S.p.A.	18- Dec- 12	10- May -16	28- Nov -17
US9828379	Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof	ABIDE THERAPEUTICS, INC.	3-Jul- 13	1- Jul- 14	28- Nov -17
US9828370	Compositions and methods for inhibiting kinases	INHIBIKASE THERAPEUTICS, INC.	23- Apr- 15	22- Apr -16	28- Nov -17
US9828346	N-myristoyl transferase inhibitors	University of Dundee	2- Sep- 08	31- Aug -15	28- Nov -17
US9828342	Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof	CITY OF HOPE	24- Feb- 12	25- Feb -13	28- Nov -17
US9827190	Intradermal delivery of immunological compositions comprising toll- like receptor 7 agonists	GLAXOSMITHKLINE BIOLOGICALS SA	1- Feb- 13	30- Jan -14	28- Nov -17
US9822339	Means and methods for influencing the stability of antibody producing cells	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM	9- Dec- 05	26- Aug -15	21- Nov -17
US9822173	Heterodimeric immunoglobulins	AMGEN INC.	21- Nov- 12	21- Nov -13	21- Nov -17
US9822165	Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external region	DANA-FARBER CANCER INSTITUTE, INC.	18- Jun- 09	18- Jun -10	21- Nov -17
US9822155	Method of preventively treating a subject at the risk of developing infections of a respiratory virus	Xiangxue Group (Hong Kong) Company Limited	9- May- 13	23- Aug -16	21- Nov -17
US9822127	GAK modulators as antivirals	The Board of Trustees of the Leland Stanford Junior University	23- Jul-14	23- Jul- 15	21- Nov -17
US9822065	Benzazepine dicarboxamide compounds	Hoffmann-La Roche Inc.	6- Mar- 15	14- Feb -17	21- Nov -17
US9821052	Reverse genetics systems	Seqirus UK Limited	31- Jul-09	30- Jul- 10	21- Nov -17
US9821051	Reducing hospitalization in elderly influenza vaccine recipients	Seqirus UK Limited	28- Oct- 10	21- Oct -11	21- Nov -17
US9816078	Compositions for increasing polypeptide stability and activity, and related methods	SOLIS BIODYNE OÜ	19- Nov- 09	11- Mar -16	14- Nov -17
US9815886	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC.	28- Oct- 14	8- Jan -15	14- Nov -17
US9815805	Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as dipeptidyl peptidase 1 inhibitors	ASTRAZENECA AB	24- Jan- 14	8- Nov -16	14- Nov -17
US9814777	Targeting lipids	Arbutus Biopharma Corporation	4- Dec- 07	22- Oct -13	14- Nov -17
US9810683	Use of live cell inteferometry with reflective floor of observation chamber to determine changes in mass of mammalian cells	The Regents of the University of California	6- May- 09	25- Nov -13	7- Nov -17
US9809845	Methods and reagents for amplifying nucleic acids	The United States of America, as represented by the Secretary, Department of Health and Human Services	6- Aug- 12	6- Aug -12	7- Nov -17
US9809796	Animal protein-free media for cultivation of cells	Baxalta GmbH	29- Oct- 04	18- May -17	7- Nov -17
US9809632	Universal protein tag for double stranded nucleic acid delivery	University of Washington Through its Center for Commercialization	23- Oct- 13	22- Oct -14	7- Nov -17
US9809591	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc.	8- Mar- 11	5- Oct -15	7- Nov -17
US9808490	Induced hepatocytes and uses thereof	ACCELERATED BIOSCIENCES CORP.	26- Nov- 14	25- Nov -15	7- Nov -17
US9803236	Microarray-based assay integrated with particles for analyzing molecular interactions	CapitalBio Corporation	6- Aug- 10	6- Aug -10	31- Oct- 17
US9803197	Particle-nucleic acid conjugates and therapeutic uses related thereto	Emory University	25- Jun- 12	27- Feb -13	31- Oct- 17
US9802937	Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors	ORIGENIS GMBH	21- Apr- 11	23- Apr -12	31- Oct- 17
US9802919	Compounds	CHIESI FARMACEUTICI S.p.A.	31- May- 16	26- May -17	31- Oct- 17
US9801948	Antimicrobial compositions and methods of use thereof	Yale University	21- Sep- 11	21- Sep -12	31- Oct- 17
US9801947	Methods and compositions for enhancing immune response	3M INNOVATIVE PROPERTIES COMPANY	10- Apr- 03	6- Oct -14	31- Oct- 17
US9801935	Soluble needle arrays for delivery of influenza vaccines	SEQIRUS UK LIMITED	20- Aug- 10	11- Oct -16	31- Oct- 17
US9801897	Delivery of RNA to trigger multiple immune pathways	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul- 10	6- Jul- 11	31- Oct- 17
US9797000	Non-target amplification method for detection of RNA splice-forms in a sample	QIAGEN GAITHERSBURG INC.	1- May- 09	30- Apr -10	24- Oct- 17
US9796979	Oligonucleotide modulators of the toll-like receptor pathway	Quark Pharmaceuticals Inc.	3- Mar- 11	28- Jul- 16	24- Oct- 17
US9796735	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	20- Jun- 07	7- Nov -14	24- Oct- 17
US9795669	Lipidated immune response modifier compound compositions, formulations, and methods	3M INNOVATIVE PROPERTIES COMPANY	17- Aug- 10	15- Dec -15	24- Oct- 17
US9795668	Delivery of self-replicating RNA using biodegradable polymer particles	GlaxoSmithKline Biologicals S.A.	6-Jul- 10	23- Nov -15	24- Oct- 17
US9795666	High-yield transgenic mammalian expression system for generating virus-like particles	Academia Sinica	5- Sep- 06	11- Feb -15	24- Oct- 17
US9791437	Multianalyte assay	Nexus Dx, Inc.	30- Apr- 07	15- Jun -15	17- Oct- 17
US9789180	D-amino acid derivative-modified peptidoglycan and methods of use thereof	The Regents of the University of California	30- Nov- 12	31- Mar -16	17- Oct- 17
US9786050	Stain-free histopathology by chemical imaging	The Board of Trustees of the University of Illinois	15- Mar- 13	14- Mar -14	10- Oct- 17
US9783595	Neutralizing GP41 antibodies and their use	The United States of America, as represented by the Secretary, Department of Health and Human Services	7- Nov- 11	2- Aug -16	10- Oct- 17
US9782470	Method of obtaining thermostable dried vaccine formulations	Merck Sharp & Dohme Corp.	16- Oct- 13	13- Oct -14	10- Oct- 17
US9782434	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution	Sonoma Pharmaceuticals, Inc.	20- Jan- 06	7- Jul- 15	10- Oct- 17
US9770504	Generating peptoid vaccines	The Board of Regents of the University of Texas System	3- May- 13	2- May -14	26- Sep -17
US9770463	Delivery of RNA to different cell types	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul- 10	7- Jun -11	26- Sep -17
US9765395	System and method for DNA sequencing and blood chemistry analysis	Nanomedical Diagnostics, Inc.	28- Apr- 14	10- Apr -15	19- Sep -17
US9765133	Antibody producing non-human mammals	Merus N.V.	27- Jun- 08	29- Apr -14	19- Sep -17
US9765071	Substituted imidazo ring systems and methods	3M INNOVATIVE PROPERTIES COMPANY	25- Nov- 03	14- Mar -16	19- Sep -17
US9764027	Outer membrane vesicles	GLAXOSMITHKLINE BIOLOGICALS SA	18- Sep- 12	18- Sep -13	19- Sep -17
US9759723	B-cell antigen presenting cell assay	University of Pittsburgh—Of the Commonwealth System of Higher Education	8- Apr- 10	21- Mar -16	12- Sep -17
US9758840	Parasite detection via endosymbiont detection	IBIS BIOSCIENCES, INC.	14- Mar- 10	11- Mar -11	12- Sep -17
US9758820	Organism identification panel	BioFire Diagnostics, LLC	2- Apr- 07	1- Apr -08	12- Sep -17
US9758775	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10- Dec- 09	14- Apr -14	12- Sep -17
US9758568	Oligopeptide-free cell culture media	Baxalta GmbH	4- Jan- 06	16- Nov -15	12- Sep -17
US9758553	Yeast strain for the production of proteins with terminal alpha-1,3- linked galactose	MERCK SHARP & DOHME CORP.	30- May- 08	2- Jul- 14	12- Sep -17
US9757478	Mutant protease biosensors with enhanced detection characteristics	Promega Corporation	11- May- 10	7- Jan -16	12- Sep -17
US9757470	Peptides for assisting delivery across the blood brain barrier	Children's Medical Center Corporation	22- May- 06	30- Apr -14	12- Sep -17
US9757446	Influenza virus vectors and uses therefor	FLUGEN, INC.	17- Mar- 14	13- Mar -15	12- Sep -17
US9757407	Treatment of viral infections by modulation of host cell metabolic pathways	The Trustees of Princeton University	1- Jun- 07	21- Dec -15	12- Sep -17
US9751945	Sortase-modified VHH domains and uses thereof	Whitehead Institute for Biomedical Research	13- Apr- 12	15- Apr -13	5- Sep -17
US9750798	Bunyaviruses with segmented glycoprotein precursor genes and methods for generating these viruses	STICHTING WAGENINGEN RESEARCH	21- May- 13	21- May -14	5- Sep -17
US9750797	Sustained release vaccine composition	VIRBAC CORPORATION	16- Jun- 04	16- Jun -05	5- Sep -17
US9750690	Circulation of components during microfluidization and/or homogenization of emulsions	NOVARTIS AG	3- Dec- 09	5- Sep -14	5- Sep -17
US9746985	System and method for detecting, collecting, analyzing, and communicating event-related information	Georgetown University	25- Feb- 08	20- Apr -11	29- Aug -17
US9746459	Antigen presenting cell assay	University of Pittsburgh—Of the Commonwealth System of Higher Education	8- Apr- 10	11- Oct -13	29- Aug -17
US9745306	2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4- D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin- 4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitors	Respivert Limited	15- Mar- 13	14- Mar -14	29- Aug -17
US9744231	Quality control methods for oil-in-water emulsions containing squalene	NOVARTIS AG	8- Nov- 06	27- Aug -13	29- Aug -17
US9744229	Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	4- Apr- 08	28- Apr -14	29- Aug -17
US9744183	Nucleic acid prodrugs and methods of use thereof	WAVE LIFE SCIENCES LTD.	6-Jul- 09	6- Jul- 10	29- Aug -17
US9738894	Short interfering RNA (siRNA) analogues	Roche Innovation Center Copenhagen A/S	21- Mar- 03	28- Mar -16	22- Aug -17
US9738624	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	21- Jun- 13	20- Jun -14	22- Aug -17
US9737618	Adeno-associated virus (AAV) glades, sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	30- Sep- 03	20- Jul- 15	22- Aug -17
US9737593	Carbon nanotube compositions and methods of use thereof	Yale University	19- Mar- 08	15- Mar -13	22- Aug -17
US9730997	Alphavirus vectors for respiratory pathogen vaccines	Novartis Vaccines and Diagnostics, Inc.	21- May- 04	20- Aug -14	15- Aug -17
US9730912	Pharmaceutical compounds	ASTEX THERAPEUTICS LIMITED	12- Oct- 06	12- Oct -07	15- Aug -17
US9727810	Spatially addressable molecular barcoding	Cellular Research, Inc.	27- Feb- 15	26- Feb -16	8- Aug -17
US9726607	Systems and methods for detecting multiple optical signals	GEN-PROBE INCORPORATED	10- Mar- 05	3- Mar -14	8- Aug -17
US9725770	Methods and compositions for identification of source of microbial contamination in a sample	The Regents of the University of California	6- Mar- 12	6- Mar -13	8- Aug -17
US9725487	Compositions and methods for measles virus inhibition	Autoimmune Technologies, LLC	4- Nov- 03	13- May -15	8- Aug -17
US9719106	Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof	The Trustees of the University of Pennsylvania	29- Apr- 13	29- Apr -14	1- Aug -17
US9719083	Bioagent detection methods	IBIS BIOSCIENCES, INC.	8- Mar- 09	8- Mar -10	1- Aug -17
US9718774	Indole carboxamide derivatives as P2X7 receptor antagonist	IDORSIA PHARMACEUTICALS LTD	12- Dec- 12	11- Dec -13	1- Aug -17
US9717755	Method of treating inflammation	Cytosorbents Corporation	1- Apr- 10	1- Apr -11	1- Aug -17
US9717749	Production of stable non-polyadenylated RNAs	Massachusetts Institute of Technology	16- Oct- 12	16- Oct -13	1- Aug -17
US9717732	Drug combination	VERONA PHARMA PLC	15- Mar- 13	17- Mar -14	1- Aug -17
US9714411	Animal protein-free media for cultivation of cells	Baxalta GmbH	29- Oct- 04	30- Nov -15	25- Jul- 17
US9714283	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC.	28- Oct- 14	2- Jul- 15	25- Jul- 17
US9714226	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29- Jul-11	13- Nov -15	25- Jul- 17
US9713641	Anti-TIGIT antigen-binding proteins and methods of use thereof	Potenza Therapeutics, Inc.	13- Feb- 17	13- Feb -17	25- Jul- 17
US9713606	Methods for treating pulmonary emphysema using substituted 2- Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	14- Mar- 13	1- Dec -15	25- Jul- 17
US9708375	Inhibitory polypeptides specific to WNT inhibitors	Amgen Inc.	15- Mar- 13	14- Mar -14	18- Jul- 17
US9707278	Methods of modulating immune responses by modifying Akt3 bioactivity	Augusta University Research Institute, Inc.	17- Apr- 14	17- Apr -15	18- Jul- 17
US9701736	Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection	New York Blood Center, Inc.	20- Oct- 10	9- Oct -14	11- Jul- 17
US9701638	Therapeutic hydroxyquinolones	Rutgers, The State University of New Jersey	9- Nov- 12	8- Nov -13	11- Jul- 17
US9700616	Arranging interaction and back pressure chambers for microfluidization	NOVARTIS AG	3- Dec- 09	22- Mar -16	11- Jul- 17
US9700614	Intranasal vaccination dosage regimen	Eurocine Vaccines AB	17- Dec- 12	17- Dec -13	11- Jul- 17
US9700558	Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist	VERONA PHARMA PLC	15- Mar- 13	17- Mar -14	11- Jul- 17
US9696247	Sample fixation and stabilisation	RNASSIST LTD.	1- Mar- 13	28- Feb -14	4- Jul- 17
US9695445	Method for production of reprogrammed cell using chromosomally unintegrated virus vector	ID Pharma Co., Ltd.	16- Jul-08	29- Jul- 15	4- Jul- 17
US9695135	Therapeutic catechols	Rutgers, The State University of New Jersey	12- May- 14	11- May -15	4- Jul- 17
US9695134	3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine- 2-carboxamide compounds	Parion Sciences, Inc.	17- Dec- 12	8- Jan -15	4- Jul- 17
US9689018	Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses	Diagnostic Hybrids, Inc.	24- Apr- 98	4- Aug -14	27- Jun- 17